BCM
AKBA icon

Bayesian Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Bayesian Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,900
Closed -$19.9K – 702
2024
Q1 		$19.9K Buy
+10,900
New +$17.4K ﹤0.01% 746
2022
Q4 		– Sell
-68,600
Closed -$22K – 755
2022
Q3 		$22K Sell
68,600
-235,500
-77% -$92.4K ﹤0.01% 641
2022
Q2 		$107K Buy
+304,100
New +$128K 0.02% 682
2020
Q4 		– Sell
-35,279
Closed -$89K – 444
2020
Q3 		$89K Buy
+35,279
New +$310K 0.02% 485

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Bayesian Capital Management's AKBA Position: Q2 2024 in Review

Bayesian Capital Management sold out of Akebia Therapeutics (AKBA) in Q2 2024, closing a stake of 10,900 shares — an estimated $19.9K sold.

Bayesian Capital Management first reported a position in AKBA in Q3 2020 and held it in 4 quarters. The position peaked at $107K in Q2 2022. 103 funds tracked by Wall St. Rank hold AKBA as of Q2 2024.

  • Bayesian Capital Management reported no remaining Akebia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 10,900 Akebia Therapeutics shares in Q2 2024, an estimated $19.9K.
  • Bayesian Capital Management first reported a position in Akebia Therapeutics in Q3 2020 and held it in 4 quarters.
  • Bayesian Capital Management's Akebia Therapeutics position peaked at $107K in Q2 2022.
  • 103 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.